Cancer Biology & Therapy最新文献_第7页

Leveraging the bacteria for enhanced cancer immunotherapy: from a perspective of synthetic biology. 利用细菌增强癌症免疫治疗：从合成生物学的角度。

IF 5.7 4区医学

Cancer Biology & Therapy Pub Date : 2026-12-31 Epub Date: 2026-06-04 DOI: 10.1080/15384047.2026.2683171

Xing Liu, Hejin Zhang, Renchun Du, Zixu Liu, Yunyun Ren, Xiao Yang

引用次数: 0

DNA polymerase theta (Polθ): a novel candidate for targeted cancer therapy. DNA聚合酶theta (Polθ)：靶向治疗癌症的新候选物。

IF 5.7 4区医学

Cancer Biology & Therapy Pub Date : 2026-12-31 Epub Date: 2026-07-28 DOI: 10.1080/15384047.2026.2703892

Bo Zhou, Zhixin Wang, Jun Qi, Fengke Liang, Haohui Liu, Yunqi Li

引用次数: 0

The tumor microenvironment in triple negative breast cancer and a strategy to improve responses to immunotherapy using cryoablation and immunostimulants. 三阴性乳腺癌的肿瘤微环境和使用冷冻消融和免疫刺激剂改善免疫治疗反应的策略。

IF 5.7 4区医学

Cancer Biology & Therapy Pub Date : 2026-12-31 Epub Date: 2026-06-05 DOI: 10.1080/15384047.2026.2683942

Ritvik Illindala, Yunpeng Yang, Tyler Mandt, Nicholas Webster, Nicole Steinmetz, Isabel Newton

{"title":"The tumor microenvironment in triple negative breast cancer and a strategy to improve responses to immunotherapy using cryoablation and immunostimulants.","authors":"Ritvik Illindala, Yunpeng Yang, Tyler Mandt, Nicholas Webster, Nicole Steinmetz, Isabel Newton","doi":"10.1080/15384047.2026.2683942","DOIUrl":"10.1080/15384047.2026.2683942","url":null,"abstract":"One in eight women will develop breast cancer (BC) over their lifetime. Triple-negative breast cancer (TNBC) accounts for up to 20% of BC cases and has fewer treatment options, greater metastatic potential, a higher risk of recurrence, and a poorer prognosis compared to other BC subtypes. Compared to hormone receptor-positive BCs, TNBC has more tumor-infiltrating lymphocytes, a higher tumor mutational burden, and greater programmed death ligand-1 (PD-L1) expression. While these features suggest greater immunogenicity, the balance of the complex TNBC tumor microenvironment (TME) is immunosuppressive. The TME leads to modest and variable effects of immune checkpoint inhibitors (ICI) for TNBC. This review explores the dysfunctional immunological state of TNBC and proposes a multi-modal strategy integrating cryoablation as a source of tumor-associated antigens (TAAs) and immunostimulatory agents to reprogram antitumor immunity. It specifically explores the strategy of combining ICI and immunostimulants with cryoablation as a source of TAAs.","PeriodicalId":9536,"journal":{"name":"Cancer Biology & Therapy","volume":"27 1","pages":"2683942"},"PeriodicalIF":5.7,"publicationDate":"2026-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13245102/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148175523","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Advances in SEC61G research: from ER translocon subunit to emerging pan-cancer oncogenic roles. SEC61G研究进展：从ER易位亚基到新出现的泛癌致癌作用

IF 5.7 4区医学

Cancer Biology & Therapy Pub Date : 2026-12-31 Epub Date: 2026-06-25 DOI: 10.1080/15384047.2026.2694136

Yu-Nan Man, Mao-Lin He

{"title":"Advances in SEC61G research: from ER translocon subunit to emerging pan-cancer oncogenic roles.","authors":"Yu-Nan Man, Mao-Lin He","doi":"10.1080/15384047.2026.2694136","DOIUrl":"10.1080/15384047.2026.2694136","url":null,"abstract":"SEC61G, the γ subunit of the Sec61 translocon, has long been regarded as a passenger co-amplification target of EGFR on chromosome 7p11.2. Recent studies have revealed its independent oncogenic functions across multiple cancers. This review proposes a mechanism-based classification of SEC61G oncogenic activities: (1) immune checkpoint regulation via canonical translocation; (2) aberrant calcium signaling; and (3) non-canonical mechanisms independent of channel functions. We further delineate the pan-cancer expression and CRISPR-Cas9 dependency landscape, highlighting a dual \"high expression, high dependency\" profile in cervical squamous cell carcinoma. We distinguish current pore-targeting Sec61 inhibitors from subunit-specific strategies and propose future directions including PROTAC degraders and PPI inhibitors. Our review identifies SEC61G as a pan‑cancer prognostic biomarker and immunotherapy response predictor, with mechanistic evidence supporting its driver roles in glioblastoma, non‑small cell lung cancer, and colorectal cancer, whereas associations in other cancers remain correlative and require further validation.","PeriodicalId":9536,"journal":{"name":"Cancer Biology & Therapy","volume":"27 1","pages":"2694136"},"PeriodicalIF":5.7,"publicationDate":"2026-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13313179/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148315940","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Research progress on the compositional characteristics of the tumor immune microenvironment and immunopredictive models in esophageal squamous cell carcinoma. 食管鳞状细胞癌肿瘤免疫微环境组成特征及免疫预测模型研究进展。

IF 5.7 4区医学

Cancer Biology & Therapy Pub Date : 2026-12-31 Epub Date: 2026-03-11 DOI: 10.1080/15384047.2026.2641263

Gongcheng Wang, Zhenzhen Li, Siyu Tan, Jing Ma, Zhiyong Yin, Juan Du, Linni Fan

{"title":"Research progress on the compositional characteristics of the tumor immune microenvironment and immunopredictive models in esophageal squamous cell carcinoma.","authors":"Gongcheng Wang, Zhenzhen Li, Siyu Tan, Jing Ma, Zhiyong Yin, Juan Du, Linni Fan","doi":"10.1080/15384047.2026.2641263","DOIUrl":"10.1080/15384047.2026.2641263","url":null,"abstract":"Esophageal cancer is one of the most prevalent malignant tumors of the digestive tract, with esophageal squamous cell carcinoma (ESCC) as its main histological type. In recent years, immunotherapeutic regimens centered on immune checkpoint inhibitors (ICIs) have achieved remarkable efficacy in patients with advanced ESCC. However, due to the heterogeneity of the tumor immune microenvironment (TIME), the degree of clinical benefit varies among patients. This heterogeneity not only affects the biological behavior of tumors but also determines the efficacy and prognosis of immunotherapy. Therefore, exploring the interactions between tumor cells and diverse immunological components inside the TIME in ESCC, as well as how to use ICIs to reshape the TIME, may bring new therapeutic opportunities for ESCC patients. This review looks at the important aspects of TIME and immunological prediction models and explores potential therapeutic strategies targeting both, providing a theoretical basis for improving immunotherapy outcomes in ESCC.","PeriodicalId":9536,"journal":{"name":"Cancer Biology & Therapy","volume":"27 1","pages":"2641263"},"PeriodicalIF":5.7,"publicationDate":"2026-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12987515/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147430777","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Molecular mechanisms and therapeutic strategies: DNA methylation in pancreatic cancer. 分子机制和治疗策略：胰腺癌中的DNA甲基化。

IF 5.7 4区医学

Cancer Biology & Therapy Pub Date : 2026-12-31 Epub Date: 2026-03-25 DOI: 10.1080/15384047.2026.2644667

Junlin Liu, Junhua Xie, Yunyu Ding

{"title":"Molecular mechanisms and therapeutic strategies: DNA methylation in pancreatic cancer.","authors":"Junlin Liu, Junhua Xie, Yunyu Ding","doi":"10.1080/15384047.2026.2644667","DOIUrl":"10.1080/15384047.2026.2644667","url":null,"abstract":"Objective: This narrative review examines DNA methylation dysregulation in pancreatic cancer, focusing on its mechanistic roles in tumorigenesis and applications in biomarkers and therapies.Methods: We analyzed experimental and clinical studies on aberrant DNA methylation patterns, emphasizing their links to invasion, metastasis, therapy resistance, and immune modulation.Results: Pancreatic cancer exhibits recurrent tumor suppressor gene hypermethylation and locus-specific hypomethylation, driving progression and resistance. Methylation-based biomarkers (tissue/cfDNA) show promise for early detection and prognostication, though evidence remains largely retrospective or preclinical.Discussion: DNA methyltransferase inhibitors, alone or combined with immunotherapy/targeted agents, demonstrate preclinical and early clinical efficacy. Key challenges include mechanistic gaps, tumor heterogeneity, and assay standardization.Conclusion: DNA methylation is a actionable regulatory layer in pancreatic cancer, but further mechanistic and clinical validation is needed for translational impact.","PeriodicalId":9536,"journal":{"name":"Cancer Biology & Therapy","volume":"27 1","pages":"2644667"},"PeriodicalIF":5.7,"publicationDate":"2026-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13020873/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147509188","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Statement of Retraction: STAT3-induced upregulation of long noncoding RNA HNF1A-AS1 promotes the progression of oral squamous cell carcinoma via activating Notch signaling pathway. 撤回声明：stat3诱导的长链非编码RNA HNF1A-AS1上调通过激活Notch信号通路促进口腔鳞状细胞癌的进展。

IF 5.7 4区医学

Cancer Biology & Therapy Pub Date : 2026-12-31 Epub Date: 2026-09-29 DOI: 10.1080/15384047.2026.2740303

引用次数: 0

Jujuboside A induces bladder cancer cell apoptosis by inhibiting ATP1A2-mediated mitochondrial energy metabolism regulation. 红枣苷A通过抑制atp1a2介导的线粒体能量代谢调节诱导膀胱癌细胞凋亡。

IF 5.7 4区医学

Cancer Biology & Therapy Pub Date : 2026-12-31 Epub Date: 2026-01-14 DOI: 10.1080/15384047.2026.2615418

Meng Zhu, Yuepeng Liu, Yumin Jia, Lixin Ren, Shuhui An, Yaxuan Wang

{"title":"Jujuboside A induces bladder cancer cell apoptosis by inhibiting ATP1A2-mediated mitochondrial energy metabolism regulation.","authors":"Meng Zhu, Yuepeng Liu, Yumin Jia, Lixin Ren, Shuhui An, Yaxuan Wang","doi":"10.1080/15384047.2026.2615418","DOIUrl":"10.1080/15384047.2026.2615418","url":null,"abstract":"Background: Conventional treatments for bladder cancer exhibit various limitations. Therefore, natural products, such as jujuboside A (JuA), have been explored for their multi-target effects and low toxicity. However, the specific effects of JuA in bladder cancer remain unclear.Objective: To determine whether JuA affects mitochondrial energy metabolism and apoptosis in bladder cancer cells by regulating the ATPase Na+/K+ transporting subunit alpha 2 (ATP1A2) expression.Methods: Differentially expressed genes (DEGs) in bladder cancer were analyzed using the GSE133624 dataset. ATP1A2 overexpression and knockdown bladder cancer cell models were constructed. Cell phenotypes and markers related to apoptosis and mitochondrial energy metabolism were assessed. Moreover, targeting effects of JuA were investigated.Results: Interleukin (IL)-6, ATP1A2, and hydroxysteroid 11-beta dehydrogenase 1 were identified as potential JuA targets, with ATP1A2 being the main target. ATP1A2 overexpression enhanced the viability and inhibited the apoptosis of bladder cancer cells and promoted mitochondrial energy metabolism in vitro, whereas ATP1A2 knockdown had the opposite effects. JuA decreased cell viability, inhibited ATP1A2 expression, and disrupted mitochondrial energy metabolism. These anticancer effects of JuA were reversed by ATP1A2 overexpression.Conclusion: This study elucidated the molecular mechanism by which JuA regulates mitochondrial energy metabolism and induces apoptosis in bladder cancer cells through targeted inhibition of ATP1A2. These findings reveal the crucial role of ATP1A2 in the energy metabolism and survival of bladder cancer cells, providing a new molecular perspective for a deeper understanding of the pathological mechanisms of bladder cancer.","PeriodicalId":9536,"journal":{"name":"Cancer Biology & Therapy","volume":"27 1","pages":"2615418"},"PeriodicalIF":5.7,"publicationDate":"2026-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12818801/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145984431","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Real-world efficacy of Bruton tyrosine kinase inhibitor based maintenance therapy in diffuse large B-cell lymphoma: a multicenter retrospective cohort study with external historical control. 基于布鲁顿酪氨酸激酶抑制剂的弥漫性大b细胞淋巴瘤维持治疗的实际疗效：一项具有外部历史对照的多中心回顾性队列研究。

IF 5.7 4区医学

Cancer Biology & Therapy Pub Date : 2026-12-31 Epub Date: 2026-04-21 DOI: 10.1080/15384047.2026.2662031

Li-Wei Lyu, Na Yao, Zi-Xian Liu, Yan-Ying Wang, Jie Li, He-Bing Zhou, Li-Hong Li, Zhen-Ling Li, Liang Wang

{"title":"Real-world efficacy of Bruton tyrosine kinase inhibitor based maintenance therapy in diffuse large B-cell lymphoma: a multicenter retrospective cohort study with external historical control.","authors":"Li-Wei Lyu, Na Yao, Zi-Xian Liu, Yan-Ying Wang, Jie Li, He-Bing Zhou, Li-Hong Li, Zhen-Ling Li, Liang Wang","doi":"10.1080/15384047.2026.2662031","DOIUrl":"10.1080/15384047.2026.2662031","url":null,"abstract":"Introduction: The selection of an optimal maintenance agent in diffuse large B-cell lymphoma (DLBCL) continues to pose a significant clinical challenge. This study aims to evaluate the prognostic impact of maintenance therapy (MT) in DLBCL.Methods: We conducted a retrospective analysis of data from DLBCL patients undergoing first-line MT at four hospitals in Beijing between January 2019 and August 2024. The REMoDL-B trial database was selected as the control group.Results: The MT group comprised 106 cases and a median follow-up duration of 25.4 months. The rates of progression and death were 11.32% (12/106) and 1.89% (2/106), respectively. The 2-y progression-free survival (PFS) and overall survival (OS) rates were 90% and 98%, respectively. The MT group demonstrated significantly superior PFS and OS compared to the control group (p = 0.024, p = 0.008). Furthermore, multivariate analysis indicated that MT (p = 0.021, OR = 0.037, 95% CI, 0.002-0.605) was an independent prognostic factor associated with improved PFS. For patients receiving Bruton tyrosine kinase inhibitors (BTKi), the 2-y PFS and OS rates were 87.6% and 97.2%, respectively, both significantly better than those of the control group (p = 0.048, p = 0.024). Despite 43.6% of patients being at high risk for central nervous system (CNS), no CNS recurrences were observed. The PFS of the MCD subtype is better than that of the A53 subtype.Conclusions: While limited by the retrospective study, our analysis raises the hypothesis that MT may correlate with improved DLBCL outcomes. A similar trend suggesting potential benefit from BTKi maintenance was noted, meriting further investigation in controlled settings.","PeriodicalId":9536,"journal":{"name":"Cancer Biology & Therapy","volume":"27 1","pages":"2662031"},"PeriodicalIF":5.7,"publicationDate":"2026-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13108342/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147763320","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Statement of Retraction: Long non-coding RNA MEG3 suppresses the development of bladder urothelial carcinoma by regulating miR-96 and TPM1. 撤回声明：长链非编码RNA MEG3通过调控miR-96和TPM1抑制膀胱尿路上皮癌的发展。

IF 5.7 4区医学

Cancer Biology & Therapy Pub Date : 2026-12-31 Epub Date: 2026-09-29 DOI: 10.1080/15384047.2026.2740300

引用次数: 0